Recombinant Human CSK9 Protein (31-692), C-His-Avi-Tagged, Biotin-Labeled

• Cat.No.: PCSK9-13H
• Product Overview: Recombinant human PCSK9 (proprotein convertase subtilisin/kexin type 9), encompassing amino acids 31-692(end). This construct contains the proprotein PCSK9 at the N-terminal encompassing amino acids 31-152. At the C-terminal this construct contains a His-tag (6×His) followed by an Avi-tag. The recombinant protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.
  PCSK9 is autocleaved to the ~14 kDa prodomain (a.a. 31-152) and the ~60 kDa mature form (a.a. 153-692(end)), which run at higher apparent MW by SDS-PAGE.

Specification

• Description: This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants.
• Source: HEK293
• Species: Human
• Tag: C-His-Avi
• Form: Aqueous buffer solution
• Molecular Mass: 74 kDa
• Protein Length: 31-692 (end)
• Purity: ≥ 90%
• Applications: Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling
• Usage: Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
• Storage: At least 6 months at –80 centigrade.
• Storage Buffer: 8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
• Shipping: At -80 centigrade
• Warning: Avoid freeze/thaw cycles.

Gene Information

• Gene Name: PCSK9 proprotein convertase subtilisin/kexin type 9 [ Homo sapiens (human) ]
• Official Symbol: PCSK9
• Synonyms: PCSK9; proprotein convertase subtilisin/kexin type 9; FH3; PC9; FHCL3; NARC1; LDLCQ1; NARC-1; HCHOLA3; proprotein convertase subtilisin/kexin type 9; convertase subtilisin/kexin type 9 preproprotein; neural apoptosis regulated convertase 1; subtilisin/kexin-like protease PC9; EC 3.4.21.-
• Gene ID: 255738
• mRNA Refseq: NM_174936
• Protein Refseq: NP_777596
• MIM: 607786
• UniProt ID: Q8NBP7

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.